awmsg logo



indacaterol/glycopyrronium (Ultibro® Breezhaler®)


Reference No. 1535

Publication date:
08/05/2014


Last review date:
08/05/2017

Appraisal information

indacaterol/glycopyrronium (Ultibro® Breezhaler®) 85 micrograms/43 micrograms inhalation powder


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Respiratory system
NMG meeting date: 22/01/2014
AWMSG meeting date: 19/02/2014
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 0814
Ministerial ratification: 07/05/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Indacaterol/glycopyrronium (Ultibro® Breezhaler®) is recommended as an option for use within NHS Wales as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download